Abstract
Autoimmune skin disease patients are screened for tuberculosis (TB) before initiation of immunosuppressive drugs via interferon gamma release assays (IGRAs). The two available tests, the QuantiFERON-TB Gold Plus (QFT-Plus, Qiagen, Hilden, Germany) and the T-SPOT.TB test (T-SPOT, Oxford Immunotec, Abingdon, UK) measure IFN-γ levels produced in response to T-cell stimulation with TB antigens. The T-SPOT test uses an enzyme-linked immunospot method rather than the enzyme-linked immunosorbent assay, the basis of the QFT-Plus test.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
